Inspire Medical Systems Inc

Inspire Medical Systems Inc(INSP)股票分析

$71.110

-1.515 (-2.13%)收盘时

Loading chart…
最高
72.750
开盘
72.250
成交量加权均价
70.77
成交量
592.14K
市值
4.02B
最低
68.439
成交额
41.90M
企业价值/息税折旧摊销前利润(TTM)
134.37

Inspire Medical Systems, Inc. is a medical technology company. The Company focuses on the development and commercialization of advanced, minimally invasive solutions for patients with obstructive sleep apnea (OSA). Its proprietary Inspire therapy is neurostimulation technology that provides safe and effective treatment for moderate to severe obstructive sleep apnea. The Company's closed-loop solution continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The Company sells its Inspire system to hospitals and ambulatory surgery centers (ASCs) in the United States (U.S.) and in select countries in Europe and Japan through a direct sales organization and sells its Inspire system in Singapore and Hong Kong through distributors. Its direct sales force engages in sales efforts and promotional activities focused on ear, nose and throat (ENT) physicians and sleep centers.

AI 分析 of Inspire Medical Systems Inc (INSP)

持有

Inspire Medical Systems is currently not a strong buy due to its recent price decline and mixed analyst ratings. The current price is $68.79, with a forward P/E of 59.17 indicating high valuation expectations. The RSI is at 47.165, suggesting the stock is neither overbought nor oversold, which may indicate a wait-and-see approach. The main risk is the significant year-to-date change of -25.45%, reflecting potential volatility ahead.

分析师评级(5)

上行空间 +104.35%
买入
3 买入
2 持有
0 卖出
当前: 71.11
最低
91.00
平均
145.31
最高
180.00

RBC Capital

2026-10-01

目标价

$75

Sector Perform

Freedom Broker

2026-09-21

目标价

$97

买入

Stifel

2026-09-11

目标价

$80

买入

Mizuho

2026-08-04

目标价

$65

跑赢大盘

JPMorgan

2026-08-04

目标价

$60

中性

估值指标

Inspire Medical Systems Inc(INSP)当前预期市盈率为 59.17,5 年平均预期市盈率为 48.04。

预期市盈率

合理
5 年均值 P/E
48.04
当前P/E
59.17
高估
298.22
低估
-202.13

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
5.20
当前EV/EBITDA
134.37
高估
174.51
低估
-164.11

预期市销率

低估
5 年均值 P/S
8.23
当前P/S
2.37
高估
13.72
低估
2.74

Alphio AI 对 INSP 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%INSP

$195.33

情景价格

基

基准

基准 · 50%INSP

$174.83

情景价格

悲

悲观

悲观 · 25%INSP

$166.61

情景价格

持有 INSP 的大户

B

Braidwell LP

+ 持有INSP

+24.47%

3个月收益率

S

Soleus Capital Management, L.P.

+ 持有INSP

-6.31%

3个月收益率

D

Deerfield Management Company, L.P.

+ 持有INSP

-6.60%

3个月收益率

A

ADAR1 Capital Management, LLC

+ 持有INSP

-12.59%

3个月收益率

INSP 常见问题 —— 由 Alphio AI 解答

Inspire Medical Systems, Inc. is a medical technology company. The Company focuses on the development and commercialization of advanced, minimally invasive solutions for patients with obstructive sleep apnea (OSA). Its proprietary Inspire therapy is neurostimulation technology that provides safe and effective treatment for moderate to severe obstructive sleep apnea. The Company's closed-loop solution continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The Company sells its Inspire system to hospitals and ambulatory surgery centers (ASCs) in the United States (U.S.) and in select countries in Europe and Japan through a direct sales organization and sells its Inspire system in Singapore and Hong Kong through distributors. Its direct sales force engages in sales efforts and promotional activities focused on ear, nose and throat (ENT) physicians and sleep centers. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Inspire Medical Systems is currently not a strong buy due to its recent price decline and mixed analyst ratings. The current price is $68.79, with a forward P/E of 59.17 indicating high valuation expectations. The RSI is at 47.165, suggesting the stock is neither overbought nor oversold, which may indicate a wait-and-see approach. The main risk is the significant year-to-date change of -25.45%, reflecting potential volatility ahead.

5 analysts cover INSP: 3 rate it Buy, 2 Hold and 0 Sell. The average price target is 145.31.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易